Therefore, the purpose of this study was to compare the effects of various PA precursors on CYC202 their ability to stimulate mTOR signaling and determine if any other phospholipid species
are also capable of stimulating mTOR signaling. Methods C2C12 myoblasts were plated at approximately 30% confluence and grown for 24 hours in 10% FBS High Glucose DMEM. Cells were switched to 2mL/well serum free high glucose DMEM (no antibiotics) for 16 hours prior to the experiment. Cells were approximately 70% confluent at the time of the experiment. Cells were then stimulated for 20 minutes with vehicle (Control) or 10, 30 or 100µM of soy-derived phosphatidylserine (S-PS, SerinAid, Chemi Nutra, White Bear Lake, MN), Alvocidib phosphatidylinositol (S-PI), phosphatidylethanolamine (S-PE), phosphatidylcholine (S-PC), PA (S-PA, Mediator,
Chemi Nutra, White Bear Lake, MN), lysophosphatidic acid (S-LPA), diacylglycerol (DAG), glycerol-3-phosphate (G3P), and egg-derived PA (E-PA). Cells were harvested in lysis buffer and subjected to immunoblotting. The ratio of P-p70-389 to total p70 was used as readout for mTOR signaling. Results S-PI, S-PE, S-PC, DAG, and G3P elicited no increase in the ratio of P-p70-389 to total p70 compared to vehicle stimulated cells. In contrast, elevated mTOR signaling was observed at all tested concentrations of S-PS (529, 588, and 457%), S-LPA (649, 866, and 1,132%), and S-PA (679, 746, and 957%; P<0.05). Egg-PA induced an 873% increase in mTOR signaling with the 100µM dose (P<0.05), whereas no significant increase was observed with the 10 or 30µM doses. Conclusions S-PA, S-LPA and S-PS are each MK-2206 clinical trial sufficient to induce an increase in mTOR signaling. Therefore, they may be capable of enhancing the anabolic effects of resistance training and contributing to muscle accretion over Interleukin-2 receptor time. Furthermore, S-PA is a more potent stimulator of mTOR signaling than PA derived from egg. Acknowledgements Supported by Chemi Nutra, White Bear Lake, MN, USA.”
“Background Few post-workout products have been properly
investigated in finished commercial form. This study was carried out in order to determine the short term (14 days) effects of Adenoflex® (World Health Products, LLC; Stamford, CT) on hematocrit levels and measures of muscular endurance. Methods Twelve recreationally active men, 28.5 ± 5 years of age and 197.1 ± 32.4 pounds body weight, took part in this double-blind, placebo-controlled trial on a volitional basis. Study participants were randomly assigned to receive either Adenoflex (AD) or Placebo (PL) for a 14 day period and were directed to take two servings per day for the first 8 days (immediately after training and five hours following) and one serving daily for the final 6 days (immediately after training). All participants completed a testing series prior to and following the supplementation period including measurement of hematocrit levels and upper extremity muscular endurance.